share_log

10-Q: Q3 2024 Earnings Report

10-Q: Q3 2024 Earnings Report

10-Q:2024财年三季报
美股SEC公告 ·  2024/11/13 11:36

Moomoo AI 已提取核心信息

ALT5 Sigma Corporation reported Q3 2024 revenue of $4.9 million with a gross profit of $2.4 million, primarily driven by its Fintech segment following the acquisition of ALT5 Subsidiary in May 2024. The company's Fintech operations achieved a 47.8% gross profit margin, while the Biotechnology segment continued development of non-addictive pain treatments.The company reported a net loss of $822,000 for Q3 2024, compared to a net loss of $214,000 in Q3 2023. Operating expenses increased to $3.6 million from $764,000 year-over-year, mainly due to the ALT5 acquisition and investments in growth initiatives. Cash and cash equivalents stood at $8.7 million as of September 28, 2024.Looking ahead, ALT5 Sigma expanded its cryptocurrency capabilities through the November 2024 acquisition of additional crypto exchange software and mobile apps. The company continues to focus on developing its dual-segment strategy, advancing both its biotechnology pipeline and fintech operations while managing a challenging competitive environment.
ALT5 Sigma Corporation reported Q3 2024 revenue of $4.9 million with a gross profit of $2.4 million, primarily driven by its Fintech segment following the acquisition of ALT5 Subsidiary in May 2024. The company's Fintech operations achieved a 47.8% gross profit margin, while the Biotechnology segment continued development of non-addictive pain treatments.The company reported a net loss of $822,000 for Q3 2024, compared to a net loss of $214,000 in Q3 2023. Operating expenses increased to $3.6 million from $764,000 year-over-year, mainly due to the ALT5 acquisition and investments in growth initiatives. Cash and cash equivalents stood at $8.7 million as of September 28, 2024.Looking ahead, ALT5 Sigma expanded its cryptocurrency capabilities through the November 2024 acquisition of additional crypto exchange software and mobile apps. The company continues to focus on developing its dual-segment strategy, advancing both its biotechnology pipeline and fintech operations while managing a challenging competitive environment.
ALT5 Sigma Corporation 发布了2024年第三季度营业收入为490万美元,毛利润为240万美元,主要得益于其金融科技部门在2024年5月收购ALT5子公司后的发展。公司的金融科技业务实现了47.8%的毛利润率,而生物技术部门则继续开发非成瘾性镇痛治疗方法。公司报告2024年第三季度净亏损为822,000美元,而2023年第三季度的净亏损为214,000美元。营业费用同比增加至360万美元,较去年的764,000美元大幅上升,主要是由于ALT5的收购及对增长计划的投资。截止到2024年9月28日,现金及现金等价物为870万美元。展望未来,ALT5 Sigma通过在2024年11月收购额外的数字货币交易所软件和移动应用,扩大了其数字货币能力。公司继续专注于推进其双部门策略,推动生物技术管道和金融科技业务的发展,同时应对严峻的竞争环境。
ALT5 Sigma Corporation 发布了2024年第三季度营业收入为490万美元,毛利润为240万美元,主要得益于其金融科技部门在2024年5月收购ALT5子公司后的发展。公司的金融科技业务实现了47.8%的毛利润率,而生物技术部门则继续开发非成瘾性镇痛治疗方法。公司报告2024年第三季度净亏损为822,000美元,而2023年第三季度的净亏损为214,000美元。营业费用同比增加至360万美元,较去年的764,000美元大幅上升,主要是由于ALT5的收购及对增长计划的投资。截止到2024年9月28日,现金及现金等价物为870万美元。展望未来,ALT5 Sigma通过在2024年11月收购额外的数字货币交易所软件和移动应用,扩大了其数字货币能力。公司继续专注于推进其双部门策略,推动生物技术管道和金融科技业务的发展,同时应对严峻的竞争环境。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息